CA2400136A1 - Perte de poids induite par la reduction du niveau de neuropeptide y - Google Patents

Perte de poids induite par la reduction du niveau de neuropeptide y Download PDF

Info

Publication number
CA2400136A1
CA2400136A1 CA002400136A CA2400136A CA2400136A1 CA 2400136 A1 CA2400136 A1 CA 2400136A1 CA 002400136 A CA002400136 A CA 002400136A CA 2400136 A CA2400136 A CA 2400136A CA 2400136 A1 CA2400136 A1 CA 2400136A1
Authority
CA
Canada
Prior art keywords
animal
weight loss
compound
feeding
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400136A
Other languages
English (en)
Inventor
Thomas M. Loftus
Craig A. Townsend
Gabriele Ronnett
M. Daniel Lane
Francis P. Kuhajda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
School of Medicine of Johns Hopkins University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400136A1 publication Critical patent/CA2400136A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5755—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)

Abstract

La présente invention concerne une technique induisant une perte de poids chez l'animal par l'administration à cet animal d'un composé qui réduit l'expression et/ou la sécrétion de neuropeptide Y (NPY). Cette effet peut être réalisé directement, indirectement ou par voie humorale. L'administration de ce composé a, de préférence, pour effet d'augmenter les taux de malonyle CoA chez l'animal. Les composés de cette invention administrés peuvent être des inhibiteurs de synthase d'acide gras (FAS), qui comprennent .alpha.-méthylène-.beta.-carboxyl-.gamma.-butyrolactones substitués ou des inhibiteurs de décarboxylase de coenzyme de malonyle (MDC). Ce composé est administré, de préférence, en quantité suffisante pour réduire la quantité et/ou la durée de l'expression et/ou de la sécrétion de NPY à des taux inférieurs à ceux que l'on observe chez des animaux maigres. Dans un autre mode préféré de réalisation de l'invention, cette administration réduira l'expression et/ou la sécrétion à des taux observés chez des animaux nourris ou rassasiés, et mieux, cette administration réduira le taux de NPY en dessous de celui des animaux nourris. Dans un mode de réalisation particulier, cette invention concerne une technique induisant une perte de poids chez l'animal par l'administration d'un composé qui inhibe les comportements alimentaires de l'animal. Cette technique convient particulièrement pour réduire la perte de poids chez l'animal chez lequel on observe un déficit de l'expression de la leptine hormonale ou chez des animaux résistant à l'action de la leptine.
CA002400136A 2000-02-16 2001-02-16 Perte de poids induite par la reduction du niveau de neuropeptide y Abandoned CA2400136A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18290100P 2000-02-16 2000-02-16
US60/182,901 2000-02-16
US20856000P 2000-06-02 2000-06-02
US60/208,560 2000-06-02
PCT/US2001/005316 WO2001060174A2 (fr) 2000-02-16 2001-02-16 Perte de poids induite par la reduction du niveau de neuropeptide y

Publications (1)

Publication Number Publication Date
CA2400136A1 true CA2400136A1 (fr) 2001-08-23

Family

ID=26878528

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400136A Abandoned CA2400136A1 (fr) 2000-02-16 2001-02-16 Perte de poids induite par la reduction du niveau de neuropeptide y

Country Status (6)

Country Link
EP (1) EP1259121A2 (fr)
JP (1) JP2003528051A (fr)
KR (1) KR20030016228A (fr)
AU (1) AU2001238515A1 (fr)
CA (1) CA2400136A1 (fr)
WO (1) WO2001060174A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313089C (zh) * 2002-02-08 2007-05-02 约翰斯霍普金斯大学医学院 刺激cpt－1物质在制备减轻体重的组合物中的用途
JP2005533107A (ja) * 2002-07-01 2005-11-04 ファスゲン，エルエルシー． 新規の化合物、それを含有する医薬組成物、およびその使用方法
EP1548131A3 (fr) * 2003-12-22 2005-07-27 F. Hoffmann-La Roche Ag Molécules cibles pour l'obésité dans le muscle squelettique
WO2005089773A1 (fr) * 2004-03-18 2005-09-29 Fasgen, Llc Regulation du comportement alimentaire par modification du bilan energetique neuronal
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5552411A (en) * 1995-05-26 1996-09-03 Warner-Lambert Company Sulfonylquinolines as central nervous system and cardiovascular agents
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US6180653B1 (en) * 1996-12-16 2001-01-30 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
JPH10287637A (ja) * 1997-04-14 1998-10-27 Banyu Pharmaceut Co Ltd アミジン誘導体
US6013622A (en) * 1998-04-15 2000-01-11 Nutriceutical Technology Corporation Method of regulating appetite and metabolism

Also Published As

Publication number Publication date
AU2001238515A1 (en) 2001-08-27
WO2001060174A3 (fr) 2002-04-25
JP2003528051A (ja) 2003-09-24
WO2001060174A2 (fr) 2001-08-23
KR20030016228A (ko) 2003-02-26
EP1259121A2 (fr) 2002-11-27

Similar Documents

Publication Publication Date Title
Müller et al. Ghrelin
Chakravarthy et al. Brain fatty acid synthase activates PPARα to maintain energy homeostasis
Sandoval et al. Targeting the CNS to treat type 2 diabetes
Abulizi et al. Multi-tissue acceleration of the mitochondrial phosphoenolpyruvate cycle improves whole-body metabolic health
Billington et al. Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism
Gault et al. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets
Makimura et al. Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting
Mahmoud et al. Growth hormone enhances excitatory synaptic transmission in area CA1 of rat hippocampus
Begg et al. Reversal of diet-induced obesity increases insulin transport into cerebrospinal fluid and restores sensitivity to the anorexic action of central insulin in male rats
Kumar et al. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R-and MC4R-deficient C57BL/6J mice
Sadagurski et al. IRS2 signaling in LepR-b neurons suppresses FoxO1 to control energy balance independently of leptin action
Jamieson et al. Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet
WO2004071458A2 (fr) Regulation de la prise alimentaire et de la production de glucose par modulation des niveaux d'acyl-coa gras de chaine longue dans l'hypothalamus
Papazoglou et al. Hypothalamic serotonin–insulin signaling cross-talk and alterations in a type 2 diabetic model
Bohlooly-y et al. Vascular function and blood pressure in GH transgenic mice
Luo et al. Experimental dopaminergic neuron lesion at the area of the biological clock pacemaker, suprachiasmatic nuclei (SCN) induces metabolic syndrome in rats
Takahashi et al. Insulin resistance and low sympathetic nerve activity in the Tsumura Suzuki obese diabetic mouse: a new model of spontaneous type 2 diabetes mellitus and obesity
Buettner et al. Hypothalamic control of hepatic glucose production and its potential role in insulin resistance
CA2400136A1 (fr) Perte de poids induite par la reduction du niveau de neuropeptide y
CA2723833A1 (fr) Procedes et compositions pour le traitement de l'obesite
Valensi et al. Cardiovascular vagosympathetic activity in rats with ventromedial hypothalamic obesity
US20070197638A1 (en) Weight loss induced by reduction in neuropeptide level
AU2006202320A1 (en) Weight loss induced by reduction in neuropeptide Y level
Wang et al. Regulation of the intracerebroventricular administration of brain-derived neurotrophic factor on baroreflex function and insulin sensitivity in rats
WO2011058364A1 (fr) Procédé de traitement et procédé de criblage

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead